Pediatric Asthma is a chronic inflammatory disorder of the airways characterized by an obstruction of airflow among children and adolescents aged 5-17 years.
DO I QUALIFY FOR THIS STUDY?
THE CFOR258 study
Eligible patients: Are 12 years of age or older
Have had an asthma diagnosis for at least one year.
Are currently taking medicine to treat their asthma
Have experienced exacerbation of asthma symptoms within the past year.
A 12-Week, Double-Blind, Randomized, Parallel-Group, Multicenter Study Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25ug, 2 Actuations Twice Daily, and Symbicort pMDI 80/4.5ug, 2 Actuations Twice Daily, Compared with Budesonide pMDI 80ug, Actuations Twice Daily, in Children Ages 6 to 12 Years with Asthma.